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TAFRO syndrome is a rare variant of idiopathic multicentric Castleman's disease, for which disseminated
non-tuberculous mycobacteria (NTM) infection must be excluded. However, due to the slow and
fastidious growth of the organisms, identification of the pathogen is often challenging. We herein
describe a case of disseminated Mycobacterium genavence infection, in which manifestations of the pa-
tient were confusingly similar to those of TAFRO syndrome. A 69-year-old Japanese man presented with
prolonged fever accompanying pain in his back and ribs on the right side. Systemic investigations
revealed thrombocytopenia, marked elevation of alkaline phosphatase, anasarca (pleural effusion and
ascites), megakaryocytosis in the bone marrow, and hepatomegaly. Magnetic resonance imaging (MRI)
showed diffuse, T1-and T2-low-intensity spotted lesions on his vertebral bodies, but biopsy showed
inconclusive results. The patient met the diagnostic criteria of TAFRO syndrome and was started on
prednisolone, which improved his general condition shortly thereafter. Blood culture after 42 days of
incubation revealed the presence of Mycobacterium; however, we considered it a contamination at that
time because no organisms grew on conventional agars, and the patient was discharged. Ten weeks after
the isolation of Mycobacterium, he developed persistent fever and was readmitted. This time, vertebral
bone mallow biopsy demonstrated a large amount of mycobacterium, which was later successfully
identified as M. genavense by sequencing analysis. Under a final diagnosis of disseminated M. genavense
infection, we treated the patient with clarithromycin, rifampicin, and ethambutol. This case highlighted
that disseminated NTM infection may follow a similar clinical course as that of TAFRO syndrome.
© 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
Mycobacterium genavense is one of the non-tuberculous myco-
bacteria (NTM) classified as an Runyon III slow-growing organism.
Since its first isolation from a patient with human immunodefi-
ciency virus (HIV) in 1992 [1], the organism has been reported to
cause disseminated infections in severely immunocompromised
patients [2,3]. Identification of the fastidious bacterium is generally
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techniques, however, have uncovered that M. genavense can cause
infection in various organs including the lungs [4], spleen [5], and
intracranial regions [6] and may cause aneurysms [7].
TAFRO syndrome is an emerging variant of idiopathic multi-
centric Castleman disease characterized by thrombocytopenia (T),
anasarca (A), fever (F), reticulin fibrosis (R), megakaryocytosis, and
organomegaly (O) [8,9]. Patients with TAFRO syndrome often
follow fatal courses, and the case fatality rate of the disease has
been reported as approximately 15% within 2 years [10]. In the
diagnostic criteria of TAFRO syndrome, various infectious diseases
including NTM-associated infections are listed as exclusion criteria
[11]. However, thus far, there are no clinical cases that report
disseminated NTM-associated infectionwas indistinguishable from
TAFRO syndrome. Herein, we report a challenging case ofous Diseases. Published by Elsevier Ltd. All rights reserved.
K. Oka et al. / J Infect Chemother 26 (2020) 1095e10991096disseminated M. genavense infection that showed a similar clinical
course as that of TAFRO syndrome.
2. Case report
A 69-year-old Japanese manwas admitted to our hospital due to
persistent fever for more than a month. His medical history
included Sjogren's syndrome and mandibular osteomyelitis. His
vital signs on admission were as follows: body temperature,
37.8 C; blood pressure,109/70mmHg; pulse rate, 80 beats/minute;
and oxygen saturation, 98% (room air). On physical examination,
there was tenderness in the back and ribs on the right side.
Otherwise, rest of the examination did not reveal any abnormal-
ities. No lymphadenopathywas seen. Blood tests showed elevations
in white blood cell count [normal range] (29,750/mL [3300e8600]),
C-reactive protein (20.31 mg/dL [<0.14]), alkaline phosphatase
(ALP, 1457 U/L [106322]), and soluble interleukin-2 receptor,
(14,280 U/mL [122496]). The serum level of lactate dehydroge-
nase, immunoglobulins (IgG, IgA, and IgM), complements, and
lymphocyte counts and fractions were all within the normal range.
The patient tested negative for T-SPOT and HIV (Table 1). Non-
contrast-enhanced magnetic resonance imaging (MRI) examina-
tion showed diffuse, T1-and T2-low-intensity lesions on the
vertebral bodies (Fig. 1A). Needle biopsy of the vertebral body was
performed under a suspected diagnosis of malignant lymphoma or
mycobacterium infection, which revealed an increase in megakar-
yocytes but not any malignant findings. We could not find any
evidence of mycobacterial infection, as acid-fast staining and
mycobacterial culture of biopsy material resulted in negative.
Respiratory discomfort developed on day 9 after admission.
Platelet counts were significantly reduced to 30,000/mL
[158,000e348,000] on day 11. Computed tomography scan showed
hepatomegaly, pleural effusion, and ascites retention in the
bladder-rectal fossa, with no lymphadenopathy (Fig. 2). Consid-
ering persistent fever accompanying elevations in inflammatory
markers, hepatomegaly, pleural effusion, ascites fluid, thrombocy-
topenia, accumulation of megakaryocytes in the bone marrow, the
patient met 3 major and 2 minor items in the diagnostic criteria for
TAFRO syndrome [8]. Additionally, the significant increase in ALP
and the absence of immunoglobulin elevation were also suggestive
of TAFRO syndrome, rather than other possible diseases [10].
Therefore, it appeared that other possible TAFRO-syndrome
mimicking diseases like malignancies and infectious diseases
have been ruled out. The patient's condition deteriorated rapidly,
and we thus decided to initiate prednisolone (PSL) at a dose of 40
mg/day. Subsequently, his general condition improved and the
levels of inflammatory markers normalized (Fig. 3). An additional
liver biopsy was not performed because the clinical course after
initiating systemic corticosteroid therapy was typically consistent
with that of the TAFRO syndrome.
Six weeks after admission, we identified a positive reaction in
mycobacterial blood culture (BACTECMyco/F Lytic bottle, BACTEC™Table 1
Laboratory testing at the first admission.
WBC 29,750 /mL TP 6
Neutrophil 82 % Alb 2
Lymphocyte 10 % T-Bil 0
Monocyte 5 % AST 2
Eosinophil 2 % ALT 1
Basophil 0 % ALP 1
Hb 7.4 g/dL LDH 1
PLT 31.2  104 /mL g-GTP 2
WBC, White blood cell count: Hb, Hemoglobin; PLT, Platelet; TP, Total protein; Alb, Alb
transferase; ALP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; g-GTP, Gamma-g
protein; PCT, Pro-calcitonin; sIL-2R, Soluble interleukin-2 receptor; IGRA, interferon-gamFX blood culture system, Becton Dickinson, Sparks, MD, USA) that
was obtained on admission day 3. Polymerase chain reaction (PCR)
tests for both Mycobacterium tuberculosis and Mycobacterium
avium-intracellular complex were negative. The culture-positive
blood medium was inoculated onto liquid media (Mycobacteria
Growth Indicator Tube (MGIT), BACTEC MGIT 960 system), Ogawa's
media, and blood agar plate, and incubated for up to 6 weeks,
which also revealed no bacterial growth. Consequently, we could
not correctly identify the bacterium at that time.
Due to successful PSL treatment, the patient was discharged on
day 64. However, his condition gradually worsened, and hence, he
was readmitted 7 weeks after discharge. Reexamination of the
vertebral bodies revealed exacerbation of the diffuse, spotted le-
sions (Fig. 1B). We re-performed a bone marrow biopsy of the
vertebral body, which revealed a large number of mycobacteria
using Ziehl-Neelsen staining. With this finding, the patient was
diagnosed with disseminated NTM infection, rather than with
TAFRO syndrome.
To provide appropriate treatment, we performed an in-depth
bacterial analysis. We re-inoculated the culture-positive blood
media into the mycobacterial blood culture system and obtained
positive results after 2 weeks of incubation. Subsequently, we
performed a direct PCR sequence for 16s rRNA and rpoB. Primers for
the targeted genes were as follows; 8UA (50-AGAGTT TGA TCM TGG
CTC AG-30) and 1485B (50-TAC GGT TAC CTT GTT ACG AC-30) for 16S
rRNA; and Forward (50-CGA CCA CTT CGG CAA CCG-30) and Reverse
(50-TCG ATC GGG CAC ATC CGG-30) for rpoB. The sequence data
were analyzed using BLAST sequence homology search programs,
and eventually, the organisms were identified as M. genavense. The
concordance rate in 16S ribosomal RNA was 99.6% (1,150bp/
1,155bp) to reported strains of M. genavense (NR_029223 and
X60070), and that in rpoB was 100% (310bp/310bp) to a reported
strain of M. genavense (AB973497). The nucleotide data were
deposited in the NCBI database with accession numbers of
LC533965 (16S ribosomal RNA, partial sequence) and LC542631
(rpoB).
Under a final diagnosis of disseminated M. genavense infec-
tion, the patient was started on combination therapy with clar-
ithromycin, rifampicin, and ethambutol. However, he developed
lower-limb paralysis due to spinal cord injury secondary to a
compression fracture of the thoracic vertebrae 8 days after
starting treatment, although bisphosphonate, as prophylaxis for
secondary osteoporosis, was started during the first hospitaliza-
tion. Although his general condition was greatly improved, he
eventually developed complete lower-limb paralysis due to the
spinal cord injury.
Later, we performed QuantiFERON®-TB Gold to detect the
presence of anti-interferon-g (IFN-g) autoantibodies as a possible
underlying cause of the disseminated NTM infection. Consequently,
we found that the positive control resulted in a negative result,
suggesting that the patient could be in a state of cellular immu-
nodeficiency due to antieIFNeg autoantibodies..3 g/dL BUN 13.5 mg/dL
.0 g/dL Cr 0.87 mg/dL
.38 mg/dL CRP 20.31 mg/dL
0 U/L PCT 0.964 ng/mL
7 U/L IgG 1673 mg/dL
457 U/L sIL-2R 14,280 U/mL
72 U/L IGRA Negative
30 U/L HIV Negative
umin; T-Bil, Total bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Amino-
lutamyl transpeptidase; BUN, Blood urea nitrogen; Cr, Creatinine; CRP, C-reactive
ma releasing assay; HIV, human immunodeficiency virus.
Fig. 1. Magnetic resonance imaging of the vertebrae. T1-and T2-low-intensity lesions were found at vertebral bodies on admission (A). The findings exacerbated, showing spotted
appearance on second admission (B).
Fig. 2. Computed tomography findings. The image shows pleural effusion (A), hepatomegaly (B), and ascites (C, arrow).
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We described a case of disseminatedM. genavense infection that
was difficult to distinguish from TAFRO syndrome. Reasons for the
difficulty in differentiation were (i) the similarity of the clinical
course and test results with those of TAFRO syndrome, (ii) the
difficulty in detecting M. genavense by routine culture procedures,
and (iii) the failure to recognize a possible immunocompromising
factor in our patient.
First, disseminated NTM infections potentially mimic TAFRO
syndrome. Typical features of TAFRO syndrome are thrombocyto-
penia (T), anasarca (A), fever (F), reticulin fibrosis (R), mega-
karyocytosis, and organomegaly (O). In addition to these findings, a
marked increase in serum ALP was observed in the present case,
which is commonly seen in cases of TAFRO syndrome [11]. Diag-
nosis of TAFRO syndrome requires excluding other inflammatory
diseases, including NTM infection, because their clinical charac-
teristics resemble each other, while their treatment strategies
contradict each other [11]. Despite the isolation of mycobacterium
from blood culture, we could not diagnose this case at an appro-
priately early stage. Because of the positive response to thetreatment with PSL, the difficulty in identifying NTM species, and
the lack of immunodeficiency that could explain the development
of NTM infection, we considered the blood-borne pathogen was
contamination. However, patients with TAFRO syndrome are pre-
disposed to be misdiagnosed with infectious diseases [9]. This case
highlighted the importance of eliminating NTM infection, even
when the clinical course of a patient is fully consistent with that of
TAFRO syndrome.
Second, identification of M. genavense was laboriousness. Of
various mycobacteria organisms,M. genavense is extremely difficult
to identify, which requires Mycobactin J for growth and thus does
not form colonies in routine solid agars. For positive identification,
a direct sequencing technique using clinical samples has been
applied in previous cases [12,13]. Hence, theremay bemore cases in
which the organism remained unidentified and disseminated in-
fections may have been overlooked.
Third, disseminated NTM infections usually occur in patients
with underlying immunodeficiencies, especially those causing a
cellular immune deficiency. Case series literature reported that
M. genavense accounted for 12.8% of disseminated NTM infections
in patients with HIV [2]. A review of M. genavense infection
Fig. 3. Clinical course of the case. ALP, alkaline phosphatase; CRP, C-reactive protein; Plt, platelet count; PSL, prednisolone.
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describing that the following background diseases were re-
ported: transplantation (40%), sarcoidosis (14%), and hemato-
poietic stem cell transplantation (7%) [3]. In the present case, no
underlying immunodeficient condition was observed. Notably,
we later found that a positive control of QuantiFERON®-TB Gold
resulted in a negative result. Severe malnutrition and lympho-
cytopenia could yield such a result; however, no such conditions
were present at the time of examination. Administration of an
immunosuppressive drug, PSL in this case, could also cause the
negative result of the positive control of the IFN-g release assay.
However, the dose of PSL was relatively lower, at 10 mg per day,
when we did the QuantiFERON®-TB Gold assay. Therefore, we
suspected another possible underlying cause of immunodefi-
ciency, such as the presence of antieIFNeg autoantibodies in this
patient. [14,15].
Recently, the importance of antieIFNeg autoantibody has been
addressed as a cause of the acquired immunodeficiency. A previous
study concluded that the antieIFNeg autoantibody was detected in
81% of Asian patients with disseminated NTM infection [16].
Another study also suggested the relation between antieIFNeg
autoantibodies and the occurrence of NTM infections [17]. In fact, a
case of disseminated M. genavence infection in a patient with
antieIFNeg autoantibody has been reported [18]. Although we did
not directly measure the serum antieIFNeg autoantibody, we
speculate that acquired immunodeficiency due to antieIFNeg
autoantibody could have triggered the onset of disseminated
M. genavence infection in our patient.
In summary, we have described a patient suffering from
disseminated M. genavence infection who manifested clinical
symptoms and findings highly suggestive of TAFRO syndrome. Due
to the difficulty in identifying the fastidious organism, initiation of
appropriate antimicrobial treatment was delayed. Disseminated
NTM infection should be suspected in patients with vertebral le-
sions, even in cases where the mycobacteria could not be detected
from the initial tissue biopsy material.Funding
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